![Steven J. Evans](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Steven J. Evans
Società | Posizione | Inizio | Fine |
---|---|---|---|
Oncolyze, Inc.
![]() Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - | |
Fondatore | - | - |
Storia della carriera di Steven J. Evans
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Founder | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Oncolyze, Inc.
![]() Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Steven J. Evans
- Esperienza